Evidence map›Paper›PMID 35291420›Full record

ArticleAmerican journal of clinical and experimental urology2022

PSA nadir predicts biochemical recurrence after external beam radiation therapy combined to high dose rate brachytherapy in the treatment of prostate cancer.

Marcos Os Coelho, Luciana Sb Dal Col, Diego M Capibaribe, Carla M Salgado, Thiago C Travassos, Vanderlei J Junior, Carlos R Monti, Leonardo O Reis

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in American journal of clinical and experimental urology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Marcos Os CoelhoUroScience, University of Campinas (Unicamp) and Pontifical Catholic University of Campinas (PU-Campinas) Campinas, São Paulo 13034-685, Brazil.
Luciana Sb Dal ColUroScience, University of Campinas (Unicamp) and Pontifical Catholic University of Campinas (PU-Campinas) Campinas, São Paulo 13034-685, Brazil.
Diego M CapibaribeUroScience, University of Campinas (Unicamp) and Pontifical Catholic University of Campinas (PU-Campinas) Campinas, São Paulo 13034-685, Brazil.
Carla M SalgadoUroScience, University of Campinas (Unicamp) and Pontifical Catholic University of Campinas (PU-Campinas) Campinas, São Paulo 13034-685, Brazil.
Thiago C TravassosUroScience, University of Campinas (Unicamp) and Pontifical Catholic University of Campinas (PU-Campinas) Campinas, São Paulo 13034-685, Brazil.
Vanderlei J JuniorUroScience, University of Campinas (Unicamp) and Pontifical Catholic University of Campinas (PU-Campinas) Campinas, São Paulo 13034-685, Brazil.
Carlos R MontiUroScience, University of Campinas (Unicamp) and Pontifical Catholic University of Campinas (PU-Campinas) Campinas, São Paulo 13034-685, Brazil.
Leonardo O ReisUroScience, University of Campinas (Unicamp) and Pontifical Catholic University of Campinas (PU-Campinas) Campinas, São Paulo 13034-685, Brazil.
Pontifícia Universidade Católica de Campinas · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionProstate cancer (PCa) is the second most prevalent neoplasm among men in the world. Its treatment has a wide spectrum of alternatives and variables, ranging from active surveillance through radio and/or brachytherapy, to surgery.

objectiveThe present work aimed to identify the predictive factors for biochemical recurrence and to evaluate the toxicity of the treatment using the association of external beam radiation therapy (EBRT) with high dose rate brachytherapy (HDR-BT) applied in the treatment of patients with prostate cancer.

methodsLongitudinal retrospective study, using a prospectively collected database between 2005 and 2014 of 186 consecutive patients records with a diagnosis of low, intermediate, or high-risk prostate cancer treated with EBRT combined with HDR-BT, in a single medical institution located in the city of Campinas, SP, Brazil (Radium Institute). PSA increase over 2 ng/ml above the nadir PSA was considered as biochemical recurrence, following the definition of the Phoenix Consensus. Continuous and clinically relevant categorical variables (age, initial PSA, delivered dose in EBRT, number of implants, number of positive cores in transrectal biopsy, use of hormone blockade, Gleason score, TNM staging, post treatment PSA and PSA Nadir) were evaluated with absolute (n) and percentage (%) values using multiple logistic regression and validated our previously described optimal PSA nadir as predictor of biochemical recurrence.

resultsPost treatment PSA was the only independent predictor of biochemical recurrence, P<0.0001. The lower the PSA nadir the lower the biochemical recurrence risk (P=0.0009). PSA nadir >1 was the best cutoff (P=0.018) determinant of biochemical recurrence. The incidence of grade 3 late toxicity to the genitourinary tract was 0.6%, and there were no cases of severe complications to the gastrointestinal tract.

conclusionExternal Beam Radiation Therapy conjugated to Brachytherapy in the treatment of Prostate Cancer has demonstrated low biochemical recurrence rates, mainly when PSA nadir <1, with low toxicity into both GU and GI tracts.

Indexed as

biochemical relapseefficacyExternal Radiotherapyhigh dose rate brachytherapyprostate cancerPSA nadirtoxicity

Identifiers

PMID35291420
PMCPMC8918392
OpenAlexW4226383812

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.